Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Bio-Rad Laboratories (BIO) Non-Current Deffered Revenue (2016)

Bio-Rad Laboratories (BIO) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $4.4 million as the latest value for Q3 2016.

On a quarterly basis, Non-Current Deffered Revenue changed N/A to $4.4 million in Q3 2016 year-over-year; TTM through Sep 2016 was $4.4 million, a N/A change, with the full-year FY2015 number at $3.7 million, changed N/A from a year prior.
Non-Current Deffered Revenue was $4.4 million for Q3 2016 at Bio-Rad Laboratories, up from $3.7 million in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $4.4 million in Q3 2016 to a low of $3.7 million in Q4 2015.